Clinical
Trials
- BTK Inhibitor BGB-3111 in Chinese Patients With Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)Condition:LymphomaMolecule:Zanubrutinib
- A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular LymphomaCondition:LymphomaMolecule:Zanubrutinib
- BGB 3111 in Combination With Obinutuzumab in Subjects With B-Cell Lymphoid MalignanciesCondition:Lymphoma, Leukemia, MyelomaMolecule:Zanubrutinib
- A Study Comparing BGB-3111 With Bendamustine Plus Rituximab in Patients With Previously Untreated CLL or SLLCondition:Leukemia, LymphomaMolecule:Zanubrutinib
- A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)Condition:LymphomaMolecule:Zanubrutinib
- Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)Condition:LymphomaMolecule:Zanubrutinib
- Study of BTK Inhibitor BGB-3111 in Subjects With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell LymphomaCondition:LymphomaMolecule:Zanubrutinib
- Study of Evaluate Efficacy and Safety of BGB-3111 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)Condition:LymphomaMolecule:Zanubrutinib
- Efficacy and Safety of BGB-3111 in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCondition:Leukemia, LymphomaMolecule:Zanubrutinib
- A Study to Investigate BGB-3111 in Chinese Patients With B-cell LymphomaCondition:LymphomaMolecule:Zanubrutinib
See All Trials
Clinical trials are an important part of our research and development efforts and help make possible access to safe and potentially life-saving treatments.